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Abstract
Background: The impact of infection with HIV on the risk of cancer in children is uncertain, particularly for those
living in sub-Saharan Africa. In an ongoing study in a paediatric oncology centre in Malawi, children (aged ≤ 15
years) with known or suspected cancers are being recruited and tested for HIV and their mothers or carers
interviewed. This study reports findings for children recruited between 2005 and 2008.
Methods: Only children with a cancer diagnosis were included. Odds ratios (OR) for being HIV positive were
estimated for each cancer type (with adjustment for age (<5 years, ≥ 5 years) and sex) using children with other
cancers and non-malignant conditions as a comparison group (excluding the known HIV-associated cancers, Kaposi
sarcoma and lymphomas, as well as children with other haematological malignancies or with confirmed non-
cancer diagnoses).
Results: Of the 586 children recruited, 541 (92%) met the inclusion criteria and 525 (97%) were tested for HIV.
Overall HIV seroprevalence was 10%. Infection with HIV was associated with Kaposi sarcoma (29 cases; OR = 93.5,
95% CI 26.9 to 324.4) and with non-Burkitt, non-Hodgkin lymphoma (33 cases; OR = 4.4, 95% CI 1.1 to 17.9) but
not with Burkitt lymphoma (269 cases; OR = 2.2, 95% CI 0.8 to 6.4).
Conclusions: In this study, only Kaposi sarcoma and non-Burkitt, non-Hodgkin lymphoma were associated with HIV
infection. The endemic form of Burkitt lymphoma, which is relatively frequent in Malawi, was not significantly
associated with HIV. While the relatively small numbers of children with other cancers, together with possible
limitations of diagnostic testing may limit our conclusions, the findings may suggest differences in the
pathogenesis of HIV-related malignancies in different parts of the world.
Background
People infected with HIV have been found to be at
increased risk of developing certain cancers [1-5] includ-
ing Kaposi sarcoma, non-Hodgkin lymphoma and con-
junctival carcinoma [6]. To date, however, the majority
of evidence has been based on studies of adults; the
impact of infection with HIV on the risk of cancer in
children is less certain. Studies in developed countries,
have suggested approximately 2.5% of children infected
with HIV will develop cancer, lower than the proportion
seen among infected adults [3]. Cancers described as
being associated with HIV in children include Kaposi
sarcoma, non-Hodgkin lymphoma and leiomyosarcoma
[3,7,8] but to date, there are few data from sub-Saharan
Africa, where the majority of HIV infected children live.
Here, we examine the association between HIV infection
and cancer among children in Blantyre, Malawi.
Results
Out of a total of 586 suspected cases of childhood can-
cer, 541 were recruited into the study. All children
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4.6%). Of the children included in the study, 284 (52%)
were diagnosed with Burkitt lymphoma, 53 (10%) with
nephroblastoma (Wilms tumour), 34 (6%) with Kaposi sar-
coma, 36 (7%) with non-Burkitt non-Hodgkin lymphomas,
28 (5%) with rhabdomyosarcoma and 22 (4%) with retino-
blastoma (Table 1). Children diagnosed with other types
of cancer and non-malignant conditions comprised 15% of
the children included in the analysis (84 children). There
were no children diagnosed with leiomyosarcoma.
There was a preponderance of male children in the
sample (59% overall) and most children (69%) resided in
rural regions of the country (Table 1). The majority of
the children were diagnosed after their fifth birthday
(65%), a pattern observed for most of the cancer group-
ings, except for those with nephroblastoma or retino-
blastoma; 35 children had missing age data. Overall,
62% of the cases had laboratory confirmed diagnoses
and 37% had the diagnosis made on clinical grounds
alone. Ten percent of all children (n = 54) tested
positive for HIV, although HIV prevalence varied by
cancer type, ranging from 0% among children with reti-
noblastoma and rhabdomyosarcoma to 77% (n = 24)
among children with Kaposi sarcoma. Of the 506 chil-
dren whose age was known, 25 children were under 18
months, and all were HIV seronegative.
HIV was strongly and positively associated with
Kaposi sarcoma (OR = 93.5, 95% CI 26.9 to 324.4, p <
0.001) and positively associated with non-Burkitt non-
Hodgkin lymphoma (OR = 4.4, 95% CI 1.1 to 17.9, p =
0.04), but not with Burkitt lymphoma (OR = 2.2, 95%
CI 0.8 to 6.4, p = 0.13; Table 2). No other cancer site or
type was significantly associated with HIV infection;
although to date, the numbers available for analysis
remain small. None of the 8 leukaemia cases and only 1
of the 10 cases of Hodgkin lymphoma were HIV seropo-
sitive. Analyses were repeated restricting to those cases
with laboratory confirmation of diagnosis: key findings
remain unchanged although confidence limits were
wider (see footnote to Table 2).
Table 1 General characteristics of 541 children with cancer diagnosed in Blantyre, Malawi
Cancer
diagnosis
n (%)
Burkitt
lymphoma
Wilms
tumour
Kaposi
sarcoma
Other
lymphoma
‡
Rhabdo-
myosarcoma
Retino-
blastoma
Other
tumours
¶
Non-malignant
conditions
†
Total**
284 (52) 53 (10) 34 (6) 36 (7) 28 (5) 22 (4) 61 (11) 23 (4) 541 (100)
Sex:
Female 112 (39) 23 (43) 13 (39) 13 (36) 11 (39) 14 (64) 26 (43) 9 (39) 221 (41)
Male 172 (61) 30 (57) 20 (61) 23 (64) 17 (61) 8 (36) 35 (57) 14 (61) 319 (59)
Age at diagnosis*
0 to 5 years
old
57 (21) 37 (74) 12 (41) 5 (15) 14 (52) 20 (95) 21 (39) 10 (45) 176 (35)
≥ 5 years old 213 (79) 13 (26) 17 (59) 28 (85) 13 (48) 1 (5) 33 (61) 12 (55) 330 (65)
Mean (se) 7.47 (0.18) 4.09 (0.34) 7.24 (0.75) 9.40 (0.68) 5.43 (0.73) 3.10 (0.36) 7.25 (0.61) 5.68 (1.04) 6.91 (0.16)
Residence
Rural 199 (71) 37 (73) 15 (45) 25 (69) 19 (68) 13 (65) 42 (70) 14 (64) 364 (69)
Urban 80 (29) 14 (27) 18 (55) 11 (31) 9 (32) 7 (35) 18 (30) 8 (36) 165 (31)
Method of diagnosis
∝
Clinical signs 38 (13) 8 (15) 18 (53) 7 (19) 8 (29) 7 (32) 8 (13) 7 (30) 101 (19)
Clinical
investigations
46 (16) 5 (9) 11 (32) 9 (25) 6 (21) 5 (23) 8 (13) 5 (22) 95 (18)
Laboratory
confirmed
197 (69) 37 (70) 5 (15) 20 (56) 13 (46) 10 (45) 43 (70) 11 (48) 336 (62)
Not
Recorded
3 (1) 3 (6) 0 (0) 0 (0) 1 (4) 0 (0) 2 (3) 0 (0) 9 (2)
HIV status
¥
Positive 20 (7) 1 (2) 24 (77) 5 (14) 0 (0) 0 (0) 1 (2) 3 (14) 54 (10)
Negative 263 (93) 51 (98) 7 (23) 31 (86) 28 (100) 16 (100) 57 (98) 18 (86) 471 (90)
‡Non-Burkitt Non-Hodgkin lymphoma and unspecified lymphomas,
¶Other tumours include: Neuroblastoma(17), Germ Cell tumours(16), Hepatic tumours(9), Bone
tumours(5), Cranial tumours (4), Soft tissue sarcomas(4), Epithelial tumours (4), Renal carcinomas(1) and Other carcinomas (1),
† Non-malignant conditions include:
Aplastic anaemia, Benign cystic teratoma, Benign mesenchymal tumour, Cellular mesoblastic nephroma, Chronic inflammation, Chronic osteomyelitis, Dental cyst,
Dentrigenous cyst, Encephalitis, Haemangioma, Liver abscess, Melanotic neuroectodermal tumour of infancy, Pleomorphic adenoma, Ranula, Salivary gland
tumour, unclassified soft tissue tumour, Teratoma, Torted ectopic spleen and Tuberculosis, *35 patients had missing age data,
∝ See methods section,
¥16
patients had missing HIV serology, **excludes 8 patients with leukaemia and 10 with Hodgkin lymphoma.
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Relative to adults, there are few published analytical epi-
demiological studies of cancer in HIV infected children,
particularly among those living in sub-Saharan Africa,
and the spectrum of cancers affecting children may be
different [4]. Unlike adults, the great majority of HIV-
infected children acquire the virus in utero or in the
first months of life when the immune system is at an
early stage of development. The proportion of children
with HIV infection who will go on to develop a malig-
nancy is at present poorly defined [3]. This study, car-
ried out in Malawi, has found clear evidence of positive
associations between HIV infection and both Kaposi sar-
coma and non-Burkitt non-Hodgkin lymphoma in chil-
dren. The relative risk of Burkitt lymphoma was raised,
although not significantly.
While Kaposi sarcoma in Malawian children was rela-
tively rare prior to the HIV epidemic [9], the number of
cases has increased during the era of HIV [10-12]. In
some sub-Saharan African countries, Kaposi sarcoma is
now one of the most common cancers in children
[13-20]. This increase is likely to reflect the prevalence
of HIV, although it is also in an area with a high back-
ground prevalence of the underlying causal virus Kapo-
si’s sarcoma-associated herpesvirus (KSHV) [21].
The increased risk for non-Burkitt non-Hodgkin lym-
phoma in association with HIV in Malawian children is
of similar magnitude to that reported for adults in
South Africa (OR = 5.0, 95% CI 2.7 to 9.5, based on 128
cases), Rwanda (OR = 12.6, 95% CI 2.2 to 54.4, based
on 26 cases), and Uganda (OR = 6.2, 95% CI 1.9 to 19.9,
based on 21 cases) [22-25]. In these studies, the relative
risk of non-Hodgkin lymphoma associated with HIV
infection is an order of magnitude lower than that
reported from developed countries [1,26]. The reasons
for this difference are not clear. Possible explanations
for the apparent lack of non-Hodgkin lymphoma among
HIV infected people in Africa include under-ascertain-
ment of the malignancy and competitive mortality from
other HIV-associated illnesses. As with all African series,
a proportion of diagnoses are made on clinical grounds
alone, and so we cannot completely exclude the possibi-
lity that some cases were misdiagnosed (e.g. tuberculosis
or other infection-associated lymphadenopathy).
A case-control study from Uganda was the first to
report an association between Burkitt lymphoma and
i n f e c t i o nw i t hH I Va m o n gc h i l d r e nl i v i n gi na na r e a
where the tumour is relatively frequent [23] (note: a
small subset of preliminary data from this study pre-
viously reported no association [27]). In 1994, no cases
of Burkitt lymphoma were found in 78 HIV positive
c h i l d r e ni nC ô t ed ’Ivoire[28], and no increase in the
incidence of childhood Burkitt lymphoma after the
onset of the HIV epidemic was noted in Zambia [16]. A
preliminary analysis of data from Malawi, published in
early 2008, identified an excess risk of Burkitt lym-
phoma - based on 11 HIV infected cases and 228 with-
out HIV (OR = 12.4, 95% CI 1.3 to 116.2)[29]. In the
updated analyses reported here, the odds ratio is lower
and no longer statistically significant, although the
adjusted prevalence of HIV is similar to that of non-
Burkitt non-Hodgkin lymphoma. However, the number
of HIV positive children with Burkitt lymphoma
reported in the literature to date is small and there
remains substantial uncertainty about the role of HIV (if
any) in the aetiology of this common malignancy among
children in parts of sub-Saharan Africa. Our results and
those of other African studies contrast with those from
Western populations, where adults and children with
AIDS are at least 1,000 times more likely to develop
Table 2 The association between HIV infection and specific cancer types
†
Adjusted prevalence of HIV infection (%)
‡
Estimate 95% CI*
Burkitt lymphoma (n = 269) 9.1 (6.0 to 13.2)
Kaposi sarcoma (n = 29) 81.8 (63.1 to 93.6)
Non-Burkitt non-Hodgkin lymphoma (n = 33) 8.9 (1.8 to 24.0)
All other cancers (n = 164) 3.5 (1.3 to 7.6)
Odds ratio for specific cancer given HIV infection compared to baseline
§ group
Odds ratio 95% CI p-value
Burkitt lymphoma (n = 269) 2.2 (0.8 to 6.4) 0.132
Kaposi sarcoma (n = 29) 93.5 (26.9 to 324.4) <0.001
Non-Burkitt non-Hodgkin lymphoma (n = 33) 4.4 (1.1-17.9) 0.038
†Individual logistic regression models of the risk of having a specific cancer based on HIV seroprevalence compared to the ‘all other cancers’ group were
adjusted for age class and gender; patients diagnosed with nephroblastoma, retinoblastoma and rhabdomyosarcoma have been included in the all other cancers
group; patients with missing age, gender or HIV status have been excluded.
‡Prevalence standardised to a population 50% female and 50% over 5 years old.
*Exact binomial confidence limits.
§Baseline group includes ‘all other cancers’ and non-malignant conditions.
NOTE: When analyses were repeated restricting to those cases with a laboratory confirmation of diagnosis, the results materially similar: Burkitt lymphoma OR 2.0,
95% CI 0.5-7.7; Kaposi sarcoma OR 46.9, 95% 3.5-631.1; Non-Burkitt non-Hodgkin lymphoma OR 3.6, 95% CI 0.6-21.5.
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[1,23,30,31], probably reflecting different pathogenetic
mechanisms.
The overall HIV seroprevalence of 10% found among
children included in this analysis was as expected in a
population of children admitted to hospital in Malawi
[32], and is similar to that seen in children with cancer
in Uganda [23]. For some cancers, the number of cases
available at the time of writing was too small to draw
reliable conclusions. Our results are broadly in line with
those reported elsewhere in Africa [9,13,23,33-35],
although data on cancer in HIV-infected children
remains scant. In developed countries, both primary
brain lymphomas and leiomyosarcomas tend to occur in
children with HIV infection [3,36-40]. Brain tumours
are difficult to diagnose in developing countries,
although 4 cases with cranial tumours were reported
here (all HIV seronegative). No cases of leiomyosarcoma
were found.
Leiomyosarcoma is a very rare tumour, occurring in
less than 2 cases per 10 million HIV negative children
per year [41], although it occurs at a much higher than
expected frequency in HIV infected children in developed
countries [3,7,8,38]. There is paucity of data from African
studies regarding the occurrence of leiomyosarcoma in
HIV infected children. It is possible that leiomyosarcoma
is under-diagnosed in this setting. Soft tissue tumours are
diagnostically challenging, with histopathological criteria
that are continuously changing. It is therefore possible
that leiomyosarcomas may be diagnosed as rhabdomyo-
sarcoma or other soft tissue tumours. Even in settings
where more advanced tumour morphology, immunophe-
notyping and other ancillary investigations are done, dis-
crepancies in diagnoses occur [42].
The results reported here are subject to the potential
problems of incomplete diagnostic verification. Labora-
tory verification of cancer diagnosis by histology and
cytology was available for 64% of all cancers. This pro-
portion varied by cancer site; being higher if the tumour
was easily accessible for biopsy. These results are typical
of studies in developing countries, where laboratory ser-
vices are limited, and compare favourably with other can-
cer series reported from Africa [13,14,43]. On the other
hand, our study had the advantage of a high ascertain-
ment of HIV status among all children with cancer
(97%), which was consistently high across all cancer
types, in contrast to a previous review of childhood can-
cer in Malawi [13]. It is possible, however, that children
with both cancer and HIV were likely to die before a
diagnosis could be made, potentially biasing our findings.
Conclusions
The impact of HIV on the risk of cancers other than
Kaposi sarcoma and non-Burkitt non-Hodgkin
lymphoma remains uncertain and is the subject of
further research. As data accrue from Malawi and else-
where, the impact of HIV on the risk of other cancer
types among children should be clarified.
Methods
Recruitment and data collection
All children aged 15 years or younger with a provisional
diagnosis of cancer admitted to the paediatric wards at
Queen Elizabeth Hospital in Blantyre, Malawi, are
recruited into a study of childhood cancer. Here we pre-
sent findings for children recruited between July 2005
and March 2008. Children with eye malignancies are
cared for on a separate mixed adult and children’s
ophthalmology ward, and recruitment for the ophthal-
mology patients was only carried out between July 2005
and July 2006. Preliminary clinical diagnoses of cancer
were made by one investigator (EMM) and confirmed
by histology, cytology or other laboratory investigations
where possible. Based on available information, all diag-
noses were coded to the International Classification of
Childhood Cancer, 3
rd edition [44]. Five local nurses
were employed and trained to recruit children and their
mothers into this study and to administer standardized
questionnaires. The parent or guardian of each child
was approached and invited to participate in the study
and provide written informed consent for their child to
be included. All children seen in the paediatric oncology
ward with suspected cancer were routinely tested for
HIV infection using Determine HIV (Abbott Labora-
tories, Illinois, USA) as a screening test and Uni-Gold™
HIV (Trinity Biotech PLC, Ireland) as a confirmatory
test, as used in other studies from Malawi [13,29,45].
Cancer diagnosis was established using varying methods.
In some instances diagnosis was based on clinical symp-
toms and signs only. Clinical investigations included X-
rays, ultrasound, blood counts and peripheral smears.
Where possible, cancer diagnoses were laboratory con-
firmed, meaning the diagnoses were histologically veri-
fied either by cytology or histology of tumour tissue.
Appropriately trained staff provided pre- and post-HIV
test counselling. Ethical approval for the study was
obtained from the Oxford Tropical Research Ethics
Committee and the Malawian College of Medicine
Research and Ethics Committee.
Statistical analyses
Initial descriptive analyses retained groupings of cancer
types with at least 20 children diagnosed. Cancer types
with fewer than 20 cases were included in a single
group called ‘other tumours’ (illustrated in Table 1). All
children diagnosed with non-Burkitt non-Hodgkin lym-
phomas (and unspecified lymphomas) were included in
a single group called ‘other lymphomas’ (shown in Table
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associated with HIV infection, children diagnosed with
nephroblastoma, retinoblastoma and rhabdomyosarcoma
were included with the smaller diagnostic groups due to
small numbers of HIV positive children with these spe-
cific cancer diagnoses (an aggregate group called ‘all
other cancers’, as illustrated in Table 2). The ‘all other
cancers’ group (n = 164) and non-malignant diagnoses
(n = 23) were grouped together to form a ‘control’ or
‘baseline” group (n = 187) of which 164 children had
complete age, sex and HIV status data. A series of
unconditional logistic regression models of the risk of
each cancer group (Burkitt lymphoma, Kaposi sarcoma
and non-Burkitt, non-Hodgkin lymphomas) being asso-
ciated with HIV infection was constructed by maximum
likelihood, adjusting for the child’s age at diagnosis
(under 5 years, and 5 years and over) and sex: the ‘base-
line’ group was used as the controls for each logistic
regression. The association between HIV status and the
risk of being diagnosed with one of the other cancer
types with more than 20 patients (nephroblastoma,
rhabdomyosarcoma or retinoblastoma) was assessed by
removing patients with the diagnosis of interest from
the baseline group and comparing them to those
patients remaining. Kaposi sarcoma and lymphomas,
which are known to be associated with HIV, were
excluded from the comparison group, as were all other
haematological malignancies (leukaemia n = 8, Hodgkin
lymphoma n = 10 and small round blue cell tumours n
= 4 (a descriptive diagnosis that might include any of
the following tumours: neuroblastoma, rhabdomyosar-
coma, non-Hodgkin lymphoma, Ewing’s sarcoma, primi-
tive neuroectodermal tumour and the blastemic
component of nephroblastoma [46])) because of possible
diagnostic overlap with lymphomas [47-49].
List of abbreviations
HIV: (Human Immunodeficiency Virus); AIDS:
(Acquired Immunodeficiency Syndrome); OR: (Odds
ratio); CI: (Confidence Interval); KSHV: (Kaposi’ss a r -
coma-associated herpesvirus).
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